ArticleJACC. Asia2024
Machine Learning-Based Discrimination of Cardiovascular Outcomes in Patients With Hypertrophic Cardiomyopathy.
Article in JACC. Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning based insights into cardiomyopathy and heart failure research: a bibliometric analysis from 2005 to 2024.Frontiers in medicine · 2025Pooled it
- Artificial intelligence and emergency physicians in the USA: enhancing clinical excellence while preserving physicians' judgment.World journal of emergency medicine · 2026Article
- Real-time dynamic prediction of in-hospital mortality in hyperglycemic crisis patients using temporal deep learning.World journal of emergency medicine · 2026Article
- Interpretative machine learning for predicting 60-day mortality in burn patients with suspected infection.World journal of emergency medicine · 2026Article
- Machine-learning-derived phenotypes of hypertensive patients using multidimensional clinical and echocardiographic data including strain imaging.European heart journal. Digital health · 2026Article
- Advancements and Applications of Artificial Intelligence in Hypertrophic Cardiomyopathy: A Comprehensive Review.Reviews in cardiovascular medicine · 2026Review
- A machine Learning-Based risk stratification using CMR volumetric and strain parameters in patients with hypertrophic cardiomyopathy.The international journal of cardiovascular imaging · 2026Article
- Artificial intelligence-empowered echocardiography: an updated review of clinical management in hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2026Review
- Beyond the chain of survival: a scoping review of artificial intelligence applications in cardiac arrest.World journal of emergency medicine · 2026Review
- Development and validation of machine learning-based in-hospital mortality predictive models for acute aortic syndrome in emergency departments.World journal of emergency medicine · 2026Article
- Artificial intelligence applications in hypertrophic cardiomyopathy: turns and loopholes.European heart journal. Digital health · 2025Review
- Cardiac myosin inhibitors in hypertrophic cardiomyopathy.Journal of cardiovascular imaging · 2025Review
- Automatic Segmentation and Evaluation of Mitral Regurgitation Using Doppler Echocardiographic Images.Bioengineering (Basel, Switzerland) · 2024Article
- Machine Learning to Predict Future Disease-Specific Outcomes: The Brave New Frontier.JACC. Asia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current risk stratification strategies for patients with hypertrophic cardiomyopathy (HCM) are limited to traditional methodologies. Objectives: The authors aimed to establish machine learning (ML)-based models to discriminate major cardiovascular events in patients with HCM. Methods: We enrolled consecutive HCM patients from 2 tertiary referral centers and used 25 clinical and echocardiographic features to discriminate major adverse cardiovascular events (MACE), including all-cause death, admission for heart failure (HF-adm), and stroke. The best model was selected for each outcome using the area under the receiver operating characteristic curve (AUROC) with 20-fold cross-validation. After testing in the external validation cohort, the relative importance of features in discriminating each outcome was determined using the SHapley Additive exPlanations (SHAP) method. Results: In total, 2,111 patients with HCM (age 61.4 ± 13.6 years; 67.6% men) were analyzed. During the median 4.0 years of follow-up, MACE occurred in 341 patients (16.2%). Among the 4 ML models, the logistic regression model achieved the best AUROC of 0.800 (95% CI: 0.760-0.841) for MACE, 0.789 (95% CI: 0.736-0.841) for all-cause death, 0.798 (95% CI: 0.736-0.860) for HF-adm, and 0.807 (95% CI: 0.754-0.859) for stroke. The discriminant ability of the logistic regression model remained excellent when applied to the external validation cohort for MACE (AUROC = 0.768), all-cause death (AUROC = 0.750), and HF-adm (AUROC = 0.806). The SHAP analysis identified left atrial diameter and hypertension as important variables for all outcomes of interest. Conclusions: The proposed ML models incorporating various phenotypes from patients with HCM accurately discriminated adverse cardiovascular events and provided variables with high importance for each outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.